Table S2 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade
Shengqing Gu(Dana-Farber Cancer Institute), X. Shirley Liu, Paloma Cejas(Dana-Farber Cancer Institute), Collin Tokheim(Johns Hopkins University), Jason L. Weirather(Dana-Farber Cancer Institute), Blair Stewig(Dana-Farber Cancer Institute), Clifford A. Meyer(Dana-Farber Cancer Institute), Peng Jiang(King Center), Klothilda Lim(Dana-Farber Cancer Institute), Myles Brown(Harvard University), Wubing Zhang(California Institute for Regenerative Medicine), Nicole Traugh(Tongji University), Jake R. Conway(Broad Institute), Ana Lako(Brigham and Women's Hospital), Scott J. Rodig(Brigham and Women's Hospital), Yingtian Xie(Dana-Farber Cancer Institute), Jingxin Fu(Tongji University), Henry W. Long(Dana-Farber Cancer Institute), Benjamin Kroger(The University of Texas Southwestern Medical Center), Michael P. Manos(Harvard University), Benjamin E. Gewurz(Brigham and Women's Hospital), Gordon J. Freeman(Dana-Farber Cancer Institute), Zexian Zeng(Peking University), F. Stephen Hodi(Harvard University), Alok K. Tewari(Harvard University), Avinash Sahu(New Mexico Department of Health), Yi Zhang(Case Western Reserve University), Ziyi Li(Ministry of Agriculture and Rural Affairs), Xiaoqing Wang(Roche (China)), Jin Hua Liang(Brigham and Women's Hospital), Evisa Gjini(Brigham and Women's Hospital), Xia Bu(Harvard University), Alba Font‐Tello(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k